In brief
The FDA has officially endorsed a new generic version of mifepristone, a drug used for medically induced abortions, which has led to criticism from anti-abortion advocates affiliated with the Trump administration. Despite federal approvals of the drug since 2000, including its first generic version in 2019, the ongoing debate surrounding abortion access remains contentious amidst evolving state laws and ongoing legal battles.
WASHINGTON (AP) — The Food and Drug Administration (FDA) has approved another generic form of the abortion pill mifepristone, further deepening the contentious debate over abortion access in the United States. This move has drawn immediate criticism from anti-abortion groups closely aligned with the previous Trump administration.
Evita Solutions, the drug manufacturer, made the announcement regarding its new low-cost mifepristone pill, which can be used for pregnancies up to 10 weeks. The approval has reignited discussions among abortion opponents, who argue for reevaluation of the drug’s safety and accessibility.
In a strongly worded statement, Students for Life Action expressed its discontent by labeling the approval a “stain” on the Trump presidency and advocating for a revocation of FDA oversight deemed necessary.
Former Trump administration health officials, including Health Secretary Robert F. Kennedy Jr., are being pressured by anti-abortion advocates to reassess mifepristone, which has been on the market since 2000 and has been consistently deemed safe by FDA researchers.
The FDA's original approval of mifepristone in 2000 has been followed by gradual changes that improved access to the drug, including the approval of its first generic version in 2019. Under the Biden administration, the FDA further permitted online prescriptions and mail-order delivery in 2021, a shift that has attracted opposition from pro-life activists.
Approval for new generic versions typically follows a standard protocol once the patent of the original drug expires, with the FDA often approving such applications within 10 months. However, Evita Solutions’ application took about four years to process.
Despite the FDA's actions, access to mifepristone remains limited in many areas of the country due to restrictive state laws against abortion and specific legal challenges targeting its use. These laws have sparked ongoing lawsuits, complicating the availability of the drug.
The FDA’s endorsement of the generic version does not, however, alter the combination therapy that often accompanies mifepristone with misoprostol, a regimen that constitutes about two-thirds of all abortions in the U.S. The combination helps to dilate the cervix and counteracts the hormone progesterone.
While the approval of the new generic pill is unlikely to directly impact access, the overall political and legal landscape continues to shape the discussion surrounding abortion rights and medical associations, which largely oppose the restrictions.
